BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RLY5016: Phase IIb data

The double-blind, international Phase IIb PEARL-HF trial in 104 patients already receiving >=1 renin-angiotensin-aldosterone system (RAAS) inhibitor showed that oral RLY5016 plus spironolactone met the primary endpoint of significantly reducing mean serum potassium levels from baseline to day...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >